Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients

AIDS Research and Human Retroviruses

Volumn 22, Issue 12, 2006, Pages 1231-1235

  Martín Carbonero, Luz ^a   Gil, Paldma ^a   García Benayas, Teresa ^a   Barreiro, Pablo ^a   Blanco, Francisco ^a   De Mendoza, Carmen ^a   Maida, Ivana ^a   González Lahoz, Juan ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR PHOSPHATE; ATAZANAVIR; DIDANOSINE; EMTRICITABINE; LAMIVUDINE; METHADONE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; THYMIDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG POTENTIATION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNSPECIFIED SIDE EFFECT; VIREMIA; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

ADENINE; ADULT; ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE; VIRAL LOAD; ZIDOVUDINE;

EID: 33846190227     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.22.1231     Document Type: Article

References (27)

1. Gulick R, Ribaudo H, Shikuma C, Lustgarten S, Squires K, Meyer W, et al.: Triple nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004;350:1850-1861.
2. Roge B, Katzenstein T, Obel N, Nielsen H, Kirk O, Pedersen C, et al.: K65R with and without S68: A new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antiviral Ther 2003;8:173-182.
3. Gerstoft J, Kirk O, Obel N, Pedersen C, Mathiesen L, Nielsen H, et al.: Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. AIDS 2003;17:2045-2052.
4. Bartlett J, Johnson J, Herrera G, Sosa N, Rodriguez A, Liao Q, et al.: Initial therapy with abacavir + lamivudine combined with efavirenz, amprenavir/ritonavir or stavudine: ESS40001 (CLASS). 15th International AIDS Conference, Bangkok, July 11-16, 2004 (abstract TuPeB4544).
5. van Leeuwen R, Katlama C, Murhy R, Squires K, Gatell J, Horban A, et al.: A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1 infected patients. AIDS 2003;17:987-999.
6. Gallant J, Rodriguez A, Weinberg W, Young B, Berger K, Lim M, et al.: Early virologic non-response to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 2005;192:1921-1930.
7. Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, et al.: Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults. JAMA 2001;285:1155-1163.
8. Jemsek J, Hutcherson P, and Harper E: Poor virologic responses and early emergences of resistance in treatment-naive HIV-infected patients receiving a once daily triple nucleoside regimen of dd1, 3TC and TDF (abstract 51). 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8-11, 2004.
9. Opravil M, Hirschel B, Lazzarin A, Furrer H, Chave J, Yerly S, et al.: A randomized trial of simplified maintenance therapy with abacavir, lamivudine and zidovudine in HIV infection. J Infect Dis 2002;185:1251-1260.
10. Martinez E, Arnaiz J, Podzamczer D, Dalmau D, Ribera E, Domingo P, et al.: Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with HIV infection. N Engl J Med 2003;349:1036-1046.
11. Hoogewerf M, Regez R, Schouten W, Weigel H, Frissen P, and Brinkman K: Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression. Lancet 2003;362:1979-1980.
12. Yeni P, Hammer S, Hirsch M, Saag M, Schechter M, Carpenter C, et al.: Treatment for adult HIV infection: 2004 recommendations of the IAS-USA Panel. JAMA 2004;292:251-265.
13. Panel on Clinical Practices for Treatment of HIV Infection convened by the US Department of Health and Human Services (DHHS): Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. http://www.aidsinfo.nih.gov//guidelines. Accessed November 24, 2005.
14. Maida I, Nuñez M, and Soriano V: Triple nucleoside regimens versus efavirenz. N Engl J Med 2004;351:717-719.
15. Miller M: K65R, TAMS and tenofovir. AIDS Rev 2004;6:22-33.
16. Kuritzkes D, Bassett R, Hazelwood J, Darren B, Barrett H, Rhodes R, et al.: Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens. J Acquir Immune Defic Syndr 2004;36:600-603.
17. Gallego O, de Mendoza C, Corral A, and Soriano V: Prevalence of drug resistance genotypes causing broad cross-resistance to nucleos(t)ide analogues. AIDS 2004;18:689-690.
18. Landman R, Peytavin G, Descamps D, Brun-Vezinet F, Benech H, Benalisherif A, et al.: Low genetic barrier to resistance is a possible cause of early virologic failures in once daily regimen of ABC, 3TC and TDF. The TONUS study (abstract 52). XI Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8-11, 2004.
19. Winston A, Pozniak A, Mandalia S, Gazzard B, Pillay D, and Nelson M: Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase. AIDS 2004;18:949-957.
20. Valer L, Martin-Carbonero L, de Mendoza C, Corral A, and Soriano V: Predictors of selection of K65R: Tenofovir use and lack of thymidine analogue mutations. AIDS 2004;18:2094-2096.
21. Johnson V, Brun-Vezinet F, Clotet B, Conway B, D'Aquila R, Demeter L, et al.: Update of the drug resistance mutations in HIV-1: 2004. Top HIV Med 2004;12:119-124.
22. Squires K: An introduction to nucleoside and nucleotide analogues. Antiviral Ther 2001;6(Suppl. 3):1-14.
23. Whitcomb J, Parkin N, Chappey C, Hellmann N, and Petropoulos C: Broad nucleoside reverse transcriptase inhibitor cross-resistance in HIV type 1 clinical isolates. J Infect Dis 2003;188:992-1000.
24. Soriano V, Puoti M, Sulkowski M, Cargnel A, Hatzakis A, Cacoub P, et al.: Care of patients with hepatitis C and HIV-coinfection. Updated recommendations from the HCV-HIV International Panel. AIDS 2004;18:1-12.
25. Berenguer J, Perez-Elias MJ, Bellon J, Knobel H, Rivas P, Gatell J, et al.: Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral-naive HIV-infected patients: Results from a large multicenter observational cohort. J Acquir Immun Defic Syndr 2006;41:154-159.
26. Wood R, Eron J, Arasteh K, Teofilo E, Trepo C, Livrozet J, et al.: A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients. Clin Infect Dis 2004;39:591-594.
27. Gathe J, Ive P, Wood R, Schurmann D, Bellos N, DeJesus E, et al.: SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ ritonavir versus twice-daily nelfmavir in naive HIV1-infected patients. AIDS 2004;18:1529-1537.